Results 221 to 230 of about 26,895 (263)
Correction to "An SGLT2 inhibitor, canagliflozin, reduces blood glucose level in the renal capillaries and protects the capillary network in the diabetic rats". [PDF]
Diabetes Obes Metabeuropepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Biochemical Pharmacology, 2016
Diabetes mellitus is a serious health issue and an economic burden, rising in epidemic proportions over the last few decades worldwide. Although several treatment options are available, only half of the global diabetic population achieves the recommended or individualized glycemic targets.
I, Dardi, T, Kouvatsos, S A, Jabbour
openaire +2 more sources
Diabetes mellitus is a serious health issue and an economic burden, rising in epidemic proportions over the last few decades worldwide. Although several treatment options are available, only half of the global diabetic population achieves the recommended or individualized glycemic targets.
I, Dardi, T, Kouvatsos, S A, Jabbour
openaire +2 more sources
Current Opinion in Cardiology, 2018
To address common concerns regarding sodium-glucose cotransporter 2 (SGLT2) inhibitor use for patients with type 2 diabetes mellitus (T2DM) in cardiovascular practice.SGLT2 inhibitors provide glycemic control and improve cardiovascular and renal endpoints in T2DM.
Erika, Opingari +3 more
openaire +2 more sources
To address common concerns regarding sodium-glucose cotransporter 2 (SGLT2) inhibitor use for patients with type 2 diabetes mellitus (T2DM) in cardiovascular practice.SGLT2 inhibitors provide glycemic control and improve cardiovascular and renal endpoints in T2DM.
Erika, Opingari +3 more
openaire +2 more sources
Cardiovascular benefit of SGLT2 inhibitors
Critical Reviews in Clinical Laboratory Sciences, 2021Patients with type 2 diabetes mellitus (T2D) are at increased risk of cardiovascular (CV) disease. Sodium glucose cotransporter 2 (SGLT2) inhibitors, also known as gliflozins, are a class of medications used to treat T2D by preventing the reabsorption of glucose filtered through the kidney and thereby facilitating glucose excretion in the urine.
Reza, Mohebi, James L, Januzzi
openaire +2 more sources
SGLT2 inhibitors and autophagy in diabetes
Cell Biochemistry and Function, 2023AbstractAutophagy is a physiological event in mammalian cells to promote cell survival and efficiency in tissues, but it may turn to be a pathological process in disease conditions such as in diabetes. Chronic hyperglycemia induces aberrant autophagy and promotes cellular death as a main underlying cause of diabetes‐related complications.
Habib Yaribeygi +4 more
openaire +2 more sources
Risk of DKA with SGLT2 inhibitors
Drug and Therapeutics Bulletin, 2021Abstract Overview of: Douros A, Lix LM, Fralick M, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis. Ann Intern Med 2020;173:417–25.
openaire +2 more sources
SGLT2 Inhibitors and Mechanisms of Hypertension
Current Cardiology Reports, 2018We sought to review currently available data on the safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes mellitus patients with hypertension.Inhibition of SGLT2 in the renal proximal tubule results in increased urinary glucose excretion and modest improvements of hemoglobin A1C.
Alexandros, Briasoulis +2 more
openaire +2 more sources
Abstract SGLT2 inhibitors were first introduced for heart failure in 2020 and are now first-line agents for all patients with symptomatic heart failure regardless of left ventricular ejection fraction. They reduce both morbidity and mortality in clinical trials with an average relative risk reduction of 23% for heart failure ...
Roy S. Gardner +3 more
openaire +2 more sources
Roy S. Gardner +3 more
openaire +2 more sources
Journal of the American College of Cardiology, 2021
Richard K. Cheng +5 more
openaire +2 more sources
Richard K. Cheng +5 more
openaire +2 more sources